US Stock Movement: Eli Lilly soared on October 30th as investment banks raised target prices, earnings exceeded expectations, and weight-loss drug sales surged

Eli Lilly October 30th Surge Analysis

Keywords: Investment banks raise target price, earnings beat expectations, weight loss drug sales surge

1. On October 30th, multiple institutions raised their target price for Eli Lilly. JPMorgan and BMO both raised their targets to $1,650, RBC raised to $1,600, Truist to $1,612, Goldman Sachs to $1,573, and Argus to $1,550.

2. On October 29th, Eli Lilly reported its third quarter 2026 results: revenue of $24.397 billion, up 39% year-on-year; adjusted earnings per share of $7.48. The company raised its full-year revenue guidance from $85–87 billion to $91–92 billion.

3. On October 29th, Eli Lilly’s global sales of Mounjaro in the third quarter reached $10.7 billion and sales of Zepbound totaled $5.4 billion, with a combined contribution exceeding $16 billion—an increase of about $6 billion compared to the third quarter of 2025. Revenue in the U.S. market reached $15.1 billion, up 34% year-on-year, mainly driven by Mounjaro and Zepbound.

(Disclaimer: This content is collected and summarized using AI technology from public information and is for reference only. It does not constitute investment advice.)